Anti-thymocyte globulin could improve the outcome of allogeneic hematopoietic stem cell transplantation in patients with highly aggressive T-cell tumors

J Yang, Y Cai, J L Jiang, L P Wan, S K Yan, C Wang, J Yang, Y Cai, J L Jiang, L P Wan, S K Yan, C Wang

Abstract

The early experiment result in our hospital showed that anti-thymocyte globulin (ATG) inhibited the proliferation of lymphoid tumor cells in the T-cell tumors. We used the ATG as the part of the conditioning regimen and to evaluate the long-term anti-leukemia effect, the safety and complication in the patients with highly aggressive T-cell lymphomas. Twenty-three patients were enrolled into this study. At the time of transplant, six patients reached first or subsequent complete response, three patients had a partial remission and 14 patients had relapsed or primary refractory disease. The conditioning regimen consisted of ATG, total body irradiation, toposide and cyclophosphamide. The complete remission rate after transplant was 95.7%. At a median follow-up time of 25 months, 16 (69.6%) patients are alive and free from diseases, including nine patients in refractory and progressive disease. Seven patients died after transplant, five from relapse and two from treatment-related complications. The incidence of grades II-IV acute graft-vs-host disease (GvHD) was 39.1%. The maximum cumulative incidence of chronic GvHD was 30%. The most frequent and severe conditioning-related toxicities observed in 8 out of 23 patients were grades III/IV infections during cytopenia. Thus, ATG-based conditioning is a feasible and effective alternative for patients with highly aggressive T-cell tumors.

Figures

Figure 1
Figure 1
Probability of overall and disease-free survival.
Figure 2
Figure 2
Probability of relapse.

References

    1. Rudiger T, Weisenburger DD, Anderson JR, Armitage JO, Diebold J, MacLennan KA, et al. Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project. Ann Oncol. 2002;13:140–149.
    1. Armitage J, Vose J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26:4124–4130.
    1. Marks DI, Forman SJ, Blume KG, Perez WS, Weisdorf DJ, Keating A, et al. A comparison of cyclophosphamide and total body irradiation with etoposide and total body irradiation as conditioning regimens for patients undergoing sibling allo- grafting for acute lymphoblastic leukemia in first or second complete remission. Biol Blood Marrow Transplant. 2006;12:438–453.
    1. Grullich G, Ziegler C, Finke J. Rabbit anti T-lymphocyte globulin induces apoptosis in peripheral blood mononuclear cell compartments and leukemia cells, while hematopoietic stem cells are apoptosis resistant. Biol Blood Marrow Transplant. 2009;15:173–182.
    1. Liu H, Qin Y, Wang X, Xie K, Yang Y, Zhu J, et al. Polyclonal rabbit antithymocyte globulin induces apoptosis and has cytotoxic effects on human leukemic cells.clinical lymphoma. Myeloma Leukemia. 2012;12:345–354.
    1. Jiang Y, Wan LP, Qin YW, Wang XR, Yan SK, Xie KC, et al. Chimerism status is correlated to acute graft-versus-host disease after allogeneic stem cell transplantation. Int J Hematol. 2014;99:323–328.
    1. Wan LP, Wang C, Liu L. Efficiacy and safety of micafungin as prophylaxis for invasive fungal disease in neutropenic patients with hematologic maliganancies. Int J Pharmacol. 2014;10:231–236.
    1. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995. pp. 825–828.
    1. Mohty M. Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. Leukemia. 2007;21:1387–1394.
    1. Du K, Hu Y, Wu K, Huang H. Long-term outcomes of antithymocyte globulin in patients with hematological malignancies undergoing myeloablative allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis. Clin Transplant. 2013;27:E91–E100.
    1. Bashir Q, Andersson BS, Fernandez-Vina M, de Padua Silva L, Giralt S, Chiattone A, et al. Unrelated donor transplantation for acute myelogenous leukemia in first remission. Biol Blood Marrow Transplant. 2011;17:1067–1071.
    1. Mohty M, Labopin M, Balère ML, Socié G, Milpied N, Tabrizi R, et al. Antithymocyte globulins and chronic graft-vs-host disease after myeloablative allogeneic stem cell transplantation from HLA-matched unrelated donors: a report from the Sociéte Française de Greffe de Moelle et de Thérapie Cellulaire. Leukemia. 2010;24:1867–1874.
    1. Scheinberg P, Fischer SH, Li L, Nunez O, Wu CO, Sloand EM, et al. Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia. Blood. 2007;109:3219–3222.
    1. Soiffer RJ, Lerademacher J, Ho V, Kan F, Artz A, Champlin RE, et al. Impact of immune modulation with anti-T-cell antibodies on the outcome of reducedintensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Blood. 2011;117:6963–6970.
    1. Hoegh-Petersen M, Amin MA, Liu Y, Ugarte-Torres A, Williamson TS, Podgorny PJ, et al. Anti-thymocyte globulins capable of binding to T and B cells reduce graft-vs-host disease without increasing relapse. Bone Marrow Transplant. 2013;48:105–114.
    1. Westphal S, Brinkmann H, Kalupa M, Wilke A, Seitz-Merwald I, Penack O. Anti-tumor effects of anti-T-cell globulin. Exp Hematol. 2014;42:875–882.
    1. Le Gouill S, Milpied N, Buzyn A, De Latour RP, Vernant JP, Mohty M, et al. Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Société Francaise de Greffe de Moëlle et de Thérapie Cellulaire. J Clin Oncol. 2008;26:2264–2271.
    1. De Witte T, Awwad B, Boezeman J, Schattenberg A, Muus P, Raemaekers J, et al. Role of allogenic bone marrowtransplantation in adolescent or adult patients with acute lymphoblastic leukaemia or lymphoblastic lymphoma in first remission. Bone Marrow Transplant. 1994;14:767–774.
    1. Feyler S, Prince HM, Pearce R, Towlson K, Nivison-Smith I, Schey S, et al. The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study. Bone Marrow Transplant. 2007;40:443–450.
    1. Kyriakou C, Canals C, Finke J, Kobbe G, Harousseau JL, Kolb HJ, et al. Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol. 2009;27:3951–3958.
    1. Kanakry JA, Kasamon YL, Gocke CD, Tsai HL, Davis-Sproul J, Ghosh N, et al. Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphoma. Biol Blood Marrow Transplant. 2013;19:602–606.
    1. Zohren F, CzibereA, Bruns I, Fenk R, Schroeder T, Gräf T, et al. Fludarabine, amsacrine, high-dose cytarabine and 12 Gy total body irradiation followed by allogeneichematopoietic stem cell transplantation is effective in patients with relapsed or high-risk acute lymphoblastic leukemia. Bone Marrow Transplant. 2009;44:785–792.
    1. Jillella AP, Doria R, Khan K, Zelterman D, Ahmad YH, Smith BR, et al. Cyclophosphamide, cytosine arabinoside and TBI as a conditioning regimen for allogeneic bone marrow transplantation in patients with leukemia. Bone Marrow Transplant. 1999;23:1095–1100.
    1. Meijer E, Cornelissen JJ, Lowenberg B, Verdonck LF. Antithymocyteglobulin as prophylaxis of graft failure and graft-versus-host disease in recipients of partially T-celldepleted grafts from matched unrelated donors: a dose-finding study. Exp Hematol. 2003;31:1026–1030.
    1. Jacobsen ED, Kim HT, Ho VT, Cutler CS, Koreth J, Fisher DC, et al. A large single-center experience with allogeneic stem-cell transplantation for peripheral T-cell non-Hodgkin lymphoma and advanced mycosis fungoides/Sezary syndrome. Ann Oncol. 2011;22:1608–1613.
    1. Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, Connors JM, et al. ALK-negative anaplastic large-cell lymphoma (ALCL) is clinically and immunophenotypically different from both ALK-positive ALCL and peripheral T-cell lymphoma not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood. 2008;111:5496–5504.
    1. Swerdlow SH, Campo E, Harris NL.WHO Classification of Tumours of Hematopoietic and Lymphoid Tissues. IARC: Lyon, 2008, pp 265–266.
    1. Soslow RA, Baergen RN, Warnke RA. B-lineage lymphoblastic lymphoma is a clinicopathologic entity distinct from other histologically similar aggressive lymphomas with blastic morphology. Cancer. 1999;85:2648–2654.
    1. Sweetenham JW, Liberti G, Pearce R, Taghipour G, Santini G, Goldstone AH. High-dose therapy and autologous bone marrow transplantation for adult patients with lymphoblastic lymphoma: Results from the European Group for Bone Marrow Transplantation. J Clin Oncol. 1994;12:1358–1365.
    1. De Witte T, Awwad B, Boezeman J, Schattenberg A, Muus P, Raemaekers J, et al. Role of allogenic bone marrowtransplantation in adolescent or adult patients with acute lymphoblastic leukaemia or lymphoblastic lymphoma in first remission. Bone Marrow Transplant. 1994;14:767–774.
    1. Besien KW, Mehra RC, Giralt SA, Kantarjian HM, Pugh WC, Khouri IF, et al. Allogeneic bone marrow transplantation for poor-prognosis lymphoma: response, toxicity and survival depend on disease histology. Am J Med. 1996;100:299–307.
    1. Levine JE, Harris RE, Loberiza Jr, FR, Armitage JO, Vose JM, Van Besien K, et al. A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma. Blood. 2003;101:2476–2482.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する